Horizon Discovery signs license agreement with Glenmark Pharmaceuticals for GS knockout CHO cell line for manufacture of biotherapeutics

Glenmark signs full commercial-use license for Horizon’s gene-edited CHO cells

 

Cambridge, UK, 30 September 2019: Horizon Discovery Group plc (LSE: HZD) (“Horizon”), a global leader in the application of gene editing and gene modulation for cell line engineering, today announced the full commercial licensing to Glenmark Pharmaceuticals, a global innovative pharmaceutical company, of its gene-edited Glutamine Synthetase (“GS”) knockout Chinese Hamster Ovary (CHO) K1 cell line. Terms of the agreement were based on stringent evaluation of the cell line by Glenmark to assess its suitability for adoption into the Company’s biomanufacturing processes. 

 

Martin Bertschinger, Deputy Director of Cell Sciences, Glenmark, explained: “After extensive evaluation, Horizon’s GS knockout CHO K1 cell line demonstrated consistently impressive performance. We generated clones with high levels of productivity and a favorable stability profile relative to our previous system. Incorporating this technology into our biomanufacturing processes enhances our ability to efficiently generate high quality cell lines.”

 

We are extremely encouraged by the adoption of our GS knockout CHO K1 cell line by Glenmark. This proprietary solution has now been licensed to over 50 companies globally, which, together with a number of confirmed Investigational New Drug (IND) filings for products expressed in the cells, demonstrates increasing industry acceptance,” commented Dirk Gewert, Business Unit Director, Horizon Discovery.These licenses have been taken as a result of an unmatched combination of high performance, transparent cell line history, supporting documentation, and attractive licensing terms. By adopting this approach, Horizon aims to empower organizations of all sizes from large pharmaceutical companies to small startups to drive efficiencies in biotherapeutic manufacturing.”

 

Horizon licenses its CHO expression system to pharmaceutical, biotechnology, and biosimilar companies, as well as contract manufacturing organizations. The system includes the GS knockout CHO K1 cell line, a comprehensive package of supporting documentation, and an expression vector supplied under license from DNATwoPointO, Inc. This biomanufacturing platform allows these companies to move from the DNA sequence of their potential biotherapeutic to clinical manufacturing as simply and rapidly as possible.

 

For further information on Horizon’s CHO expression system, please visit: https://www.horizondiscovery.com/bioproduction/cho-cells

 

ENDS

 

For further information from Horizon Discovery Group plc, please contact:

 

Zyme Communications (Trade and Regional Media)

Katie Odgaard

Tel: +44 (0)7787 502 947

Email: katie.odgaard@zymecommunications.com

 

To opt-out from receiving press releases from Zyme Communications please email info@zymecommunications.com. To view our privacy policy, please click here.

 

About Horizon Discovery Group plc www.horizondiscovery.com

Horizon Discovery Group plc (LSE: HZD) ("Horizon") drives the application of gene editing and gene modulation within the global life science market – supporting scientists on the path from research to therapy.

 

Built upon more than a decade of experience in the engineering of cell lines, Horizon offers an unmatched portfolio of tools and services to help scientists gain a greater understanding of gene function, identify genetic drivers behind human disease, deliver biotherapeutics, cellular and gene therapies for precision medicine as well as develop and validate diagnostic workflows.

 

Horizon’s solutions enable almost any gene to be altered, or its function modulated, in human and other mammalian cell lines.

 

The Company’s customers include many of the world’s foremost academic institutes, global pharmaceutical and biotechnology companies as well as clinical diagnostic laboratories. Insight into the challenges faced by these organizations enables the company to focus efforts on development of innovative solutions that not only differentiate the company’s offering, but also fuel development of the next wave of precision medicines.

 

Horizon is headquartered in Cambridge, UK with offices in USA and Japan.  The Group is listed on the London Stock Exchange's AIM market under the ticker HZD.

 

About Glenmark Pharmaceuticals

Glenmark Pharmaceuticals is a research-driven, global, integrated pharmaceutical organization with operations in more than 80 countries. It is ranked among the top 75 Pharma & Biotech companies of the world in terms of revenue (SCRIP 100 Rankings published in the year 2018). Glenmark is a leading player in the discovery of new molecules both NCEs (new chemical entity) and NBEs (new biological entity). Glenmark has several molecules in various stages of clinical development and is focused in the areas of oncology, immunology and pain. For more information, please visit www.glenmarkpharma.com

For further information, please contact:
Robyn Jackson
+1 (347) 452-0242